We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+12.38%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.12B
AUM Growth
+$545M
Cap. Flow
+$493M
Cap. Flow %
11.96%
Top 10 Hldgs %
48.24%
Holding
158
New
26
Increased
23
Reduced
71
Closed
24

Top Buys

Rank Stock Value
1
KLRS
Kalaris Therapeutics
KLRS
+$69M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$68.4M
3
BEKE icon
KE Holdings
BEKE
+$43.5M
4
IGMS
IGM Biosciences
IGMS
+$40.8M
5
ITOS
iTeos Therapeutics
ITOS
+$29.4M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$42.9M
2
PYPL icon
PayPal
PYPL
+$34.8M
3
AVTR icon
Avantor
AVTR
+$34M
4
ARGX icon
argenx
ARGX
+$30.2M
5
Z icon
Zillow
Z
+$22.1M

Sector Composition

Rank Sector Weight
1 Healthcare 57.47%
2 Consumer Discretionary 10.25%
3 Technology 2.5%
4 Real Estate 1.29%
5 Materials 0.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGTX icon
26
TG Therapeutics
TGTX
$8.15B
$40.1M 0.97%
1,500,000
-250,000
-14% -$5.75M
XLI icon
27
CALL
State Street Industrial Select Sector SPDR ETF
XLI
$32.3B
$38.5M 0.93%
500,000
+50,000
+11% +$3.74M
NBP
28
NovaBridge Biosciences American Depositary Shares
NBP
$191M
$34.1M 0.83%
725,000
+401,000
+124% +$13.2M
NG icon
29
NovaGold Resources
NG
$2.52B
$30.9M 0.75%
2,600,000
– –
DCPH
30
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$30.8M 0.75%
600,000
-50,000
-8% -$2.45M
GOSS icon
31
Gossamer Bio
GOSS
$92M
$29.3M 0.71%
2,358,968
-300,000
-11% -$3.98M
ATRA icon
32
Atara Biotherapeutics
ATRA
$69.8M
$29.2M 0.71%
90,000
-10,000
-10% -$3.41M
ALBO
33
DELISTED
Albireo Pharma Inc
ALBO
$28.4M 0.69%
851,405
+351,045
+70% +$10.2M
TPTX
34
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$28.4M 0.69%
325,000
-25,000
-7% -$1.74M
QURE icon
35
uniQure
QURE
$2.77B
$27.6M 0.67%
750,000
-250,000
-25% -$10.2M
AGEN
36
Agenus
AGEN
$277M
$27.6M 0.67%
351,555
+206,347
+142% +$16.1M
ITOS
37
DELISTED
iTeos Therapeutics
ITOS
$27M 0.66%
+1,094,047
New +$29.4M
TSHA icon
38
Taysha Gene Therapies
TSHA
$1.58B
$25.6M 0.62%
+1,140,882
New +$26.8M
MS icon
39
CALL
Morgan Stanley
MS
$321B
$24.2M 0.59%
+500,000
New +$25.2M
AAPL icon
40
CALL
Apple
AAPL
$5.01T
$23.2M 0.56%
+200,000
New +$21.8M
C icon
41
CALL
Citigroup
C
$215B
$21.6M 0.52%
500,000
-500,000
-50% -$24.9M
TRIL
42
DELISTED
Trillium Therapeutics Inc.
TRIL
$21.3M 0.52%
1,500,000
+547,000
+57% +$5.45M
MRNA icon
43
Moderna
MRNA
$21.7B
$21.2M 0.52%
300,000
-200,000
-40% -$13.9M
STNE icon
44
StoneCo
STNE
$2.65B
$21.2M 0.51%
400,000
+110,000
+38% +$5.25M
Z icon
45
Zillow
Z
$7.81B
$20.3M 0.49%
200,000
-283,000
-59% -$22.1M
TBIO
46
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$19.1M 0.46%
1,400,000
-200,000
-13% -$3.08M
RUBY
47
DELISTED
Rubius Therapeutics, Inc
RUBY
$18.9M 0.46%
3,778,913
-73,428
-2% -$389K
MRSN
48
DELISTED
Mersana Therapeutics
MRSN
$18.6M 0.45%
40,000
+8,000
+25% +$4.04M
ADVM
49
DELISTED
Adverum Biotechnologies
ADVM
$18.5M 0.45%
180,000
+90,000
+100% +$13.5M
TCOM icon
50
Trip.com Group
TCOM
$29.2B
$17.8M 0.43%
570,000
-30,000
-5% -$853K
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2020 Portfolio in Review

As of Q3 2020, Artal Group held 158 positions worth $4.12B, up 15% from $3.57B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group deployed $493M of net new capital in Q3 2020, opening 26 new positions and adding to 23 existing holdings. Its largest new stake was Kalaris Therapeutics: 101,016 shares worth $63.9M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 62% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was argenx, an estimated $30.2M trimmed.

  • Artal Group's largest Q3 2020 buy was Kalaris Therapeutics: 101,016 shares worth $63.9M.
  • Artal Group added most to Agenus in Q3 2020, an estimated $16.1M increase.
  • Artal Group's biggest Q3 2020 reduction was argenx, cutting an estimated $30.2M.
  • Artal Group fully exited Blueprint Medicines in Q3 2020, selling an estimated $42.9M.
  • Artal Group's ten largest holdings make up 48% of its $4.12B portfolio in Q3 2020.
  • Artal Group opened 26 new positions and closed 24 in Q3 2020.
  • Artal Group's portfolio value rose 15% quarter-over-quarter to $4.12B.

Based on Artal Group's 13F filing for Q3 2020, filed 13 Nov 2020.